Evaluation of Stem Cell-Derived Cellular Therapy Products

5Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Although there is an increase in the development of new cellular therapies, few guidelines have been published to assist in the design of preclinical studies. As no product and therapeutic intention is entirely alike regulators and Contract Research Organizations need to treat each project on a case-by-case basis. One of the most important considerations in study design is to retain all tissues from the study, thereby allowing for further analysis of tissues should unexpected effects be seen in clinical studies. Input from the pathologist at the earliest stages of study design regarding animal selection, cell markers, and phased tissue examination improves the scientific integrity of the study.

Cite

CITATION STYLE

APA

Bradley, A. E., & Black, L. (2021). Evaluation of Stem Cell-Derived Cellular Therapy Products. Toxicologic Pathology, 49(7), 1288–1293. https://doi.org/10.1177/0192623319897898

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free